Sign in | Register

United States of America

Discover our full story

A proven pioneer and partner to the diagnostics industry

We are an R&D-driven company constantly developing new technologies and unique biomarkers with high clinical value. Read more.

Find your product

Chances are you already know us

Over the years, since our foundation in Japan in 1950, we have built a strong tradition of innovating, developing, manufacturing and marketing high-quality in vitro diagnostics testing solutions worldwide.

The acquisition of Centocor Diagnostics, CanAg Diagnostics and Innogenetics have further bolstered our capabilities and expertise in various clinical areas.

Today, working closely with one of the world’s top commercial laboratories (SRL, Inc.), another entity within the H.U. Group, Fujrebio combines expertise and experience for the diagnostics market that is more potent than ever.

Read about Fujirebio

Product categories:

Discover our solutions

Instruments

Our LUMIPULSE^® G, TENDIGO^™, RoboBlot^™, Auto-LIA^™, Auto-LiPA^™ and other instruments.

Kits for fully automated testing

Our range of fully automated Lumipulse^® G assays.

Kits for manual or semi-automated testing

Our classic CanAg^®, INNO-LIA^®, INNO-LiPA^®, INNOTEST^® and other testing solutions.

Software

Our LIRAS^® software solutions for reading and interpretation.

Controls

Our various control solutions.

Raw materials

Our widely used ranges of antibodies and antigens.

Products by diseases and disorders:

Autoimmune diseases

Bone metabolism

Genetic disorders

Infectious diseases

Interstitial pneumonia

Neurodegeneration

Transplantation

Fujirebio and Sysmex expand CDMO partnership into the field of neurodegenerative diseases under their immunoassay collaboration

Fujirebio Holdings, Inc. (President and CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have...

Read more

Fujirebio and Sysmex enter into basic agreement on business collaboration in the field of Immunoassay

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru...

Read more

Fujirebio joins the Global Health Innovative Technology (GHIT) Fund

H.U. Group Holding Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (President and CEO: Goki Ishikawa; Head Office: Minato-ku...

Read more

Beckman Coulter and Fujirebio partner to bolster access to patient-friendly, blood-based Alzheimer’s disease test therapeutics

Collaboration builds upon Fujirebio expertise in neurodegenerative disease assays and Beckman Coulter’s high sensitivity, high throughput...

Read more

Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse® G ApoE4 and Lumipulse® G Pan-ApoE assays for Research Use Only

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G...

Read more

Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests

Gent, Belgium, Malvern PA, USA, and Tokyo, Japan, March 28, 2023 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today...

Read more

AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. announce strategic partnership to advance biomarker development for Alzheimer’s disease and neurodegeneration

San Diego, CA and Tokyo, Japan and Malvern, PA – March 8, 2023 – Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics...

Read more

Fujirebio acquires Fluxus to accelerate new platform development based on ultra-high sensitivity detection technology

H.U. Group Holding Inc., and its wholly-owned subsidiary, Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Shinjuku-ku...

Read more

59th PAMET ANNUAL CONVENTION

Manila, Philippines

Thumbnail

USPALZ 2023 (Congrès National des Unités de Soins…

Issy-les-Moulineaux (Paris), France

Thumbnail

Medlab Middle East 2024

Dubai, United Arab Emirates

Healthcare for You.

With our deep involvement in human health, we aim to be a group that contributes to the development of healthcare through trust and innovation.

Read more about us

Insight articles

Dec 1, 2023

Alzheimer's disease

CTAD 2023 – Spotlight on recent advances in blood-based biomarkers for Alzheimer’s disease

Read more

A risk-based approach for post-treatment detection of recurrent CIN

Nov 6, 2023

HPV

A risk-based approach for post-treatment detection of recurrent CIN

Read more

Sep 7, 2023

HPV

Video: DNA methylation and improved detection of cervical pre-cancers in screening, diagnosis and post-treatment management

Read more

Better care for pregnant women diagnosed with precancerous cervical lesions

Aug 17, 2023

HPV

Better care for pregnant women diagnosed with precancerous cervical lesions

Read more

Jul 10, 2023

Alzheimer's disease

IVDR status update for Fujirebio’s Neuro products

Read more

May 31, 2023

HPV

Cervical cancer screening being reviewed – the role of distinguishing individual HPV genotypes

Read more

Choose your country or region

Select your country or region

I am a healthcare professional

The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.

site by D'M&S